Imatinib treatment reduces brain injury in a murine model of traumatic brain injury
Authors:
- Enming J. SuESEnming J. Su
- Linda FredrikssonLFLinda Fredriksson
- Mia KanzawaMKMia Kanzawa
- Shannon MooreSMShannon Moore
- Erika FolestadEFErika Folestad
- Tamara K. StevensonTSTamara K. Stevenson
- Ingrid NilssonINIngrid Nilsson
- Maithili SashindranathMSMaithili Sashindranath
- Gerald P. SchielkeGSGerald P. Schielke
- Mark WarnockMWMark Warnock
- Kris MannKMKris Mann
Open Access
- 7 October 2015
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 9, 385
Abstract
Current therapies for Traumatic brain injury (TBI) focus on stabilizing individuals and on preventing further damage from the secondary consequences of TBI. A major complication of TBI is cerebral edema, which can be caused by the loss of blood brain barrier (BBB) integrity. Recent studies in several CNS pathologies have shown that activation of latent platelet derived growth factor-CC (PDGF-CC) within the brain can promote BBB permeability through PDGF receptor α (PDGFRα) signaling, and that blocking this pathway improves outcomes. In this study we examine the efficacy for the treatment of TBI of an FDA approved antagonist of the PDGFRα, Imatinib. Using a murine model we show that Imatinib treatment, begun 45 minutes after TBI and given twice daily for 5 days, significantly reduces BBB dysfunction. This is associated with significantly reduced lesion size 24 hours, 7 days, and 21 days after TBI, reduced cerebral edema, determined from apparent diffusion co-efficient (ADC) measurements, and with the preservation of cognitive function. Finally, analysis of CSF from human TBI patients suggests a possible correlation between high PDGF-CC levels and increased injury severity. Thus, our data suggests a novel strategy for the treatment of TBI with an existing FDA approved antagonist of the PDGFRα.Keywords
This publication has 59 references indexed in Scilit:
- Imatinib Ameliorates Neuroinflammation in a Rat Model of Multiple Sclerosis by Enhancing Blood-Brain Barrier Integrity and by Modulating the Peripheral Immune ResponsePLOS ONE, 2013
- Imatinib Enhances Functional Outcome after Spinal Cord InjuryPLOS ONE, 2012
- Blood–Brain Barrier Pathophysiology in Traumatic Brain InjuryTranslational Stroke Research, 2011
- PDGFR‐α inhibition preserves blood‐brain barrier after intracerebral hemorrhageAnnals of Neurology, 2011
- Blood–brain barrier breakdown as a therapeutic target in traumatic brain injuryNature Reviews Neurology, 2010
- A Method for Reducing Misclassification in the Extended Glasgow Outcome ScoreJournal of Neurotrauma, 2010
- Amyloid precursor protein secretases as therapeutic targets for traumatic brain injuryNature Medicine, 2009
- Exaggerated emotional behavior in mice heterozygous null for the sodium channel Scn8a (Nav1.6)Genes, Brain and Behavior, 2008
- Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic strokeNature Medicine, 2008
- Efficacy of Progesterone following a Moderate Unilateral Cortical Contusion InjuryJournal of Neurotrauma, 2008